ReviewTranslational lung cancer research2026
Advances in the research on radiotherapy for lung cancer: a 2025 review.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reviewed radiotherapy-related studies on lung cancer presented at the 2025 major international conferences [American Society of Clinical Oncology (ASCO), World Conference on Lung Cancer (WCLC), European Society for Medical Oncology (ESMO), and American Society for Radiation Oncology (ASTRO)] or published in high-impact journals. The studies were classified by pathological type [non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)] and analyzed according to different tumor stages. Research showed that the combination of immunotherapy and stereotactic body radiotherapy (SBRT) failed to improve overall survival (OS) and progression-free survival (PFS) in early-stage NSCLC, so its combined application requires caution. In locally advanced NSCLC, EA5181 and SKYSCRAPER-03 trials identified that durvalumab administered concurrently with definitive chemoradiotherapy (dCRT) or atezolizumab + tiragolumab combination following concurrent chemoradiation therapy (cCRT) failed to improve PFS. The PACIFIC regimen remains the current standard treatment. R-ALPS trial indicated that, as consolidation therapy after dCRT, immunotherapy combined with anti-angiogenic agents achieved a prolongation of PFS with manageable treatment-related adverse events (TRAEs). In advanced NSCLC, NROG-002 and NorthStar trials demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) plus thoracic radiotherapy (TRT) or local consolidation therapy (LCT) can significantly improve patients' PFS. The results expanded the traditional "oligometastasis" definition from "oligo-sites" to "oligo-organs". For SCLC treatment, hypofractionated radiotherapy (HyPORT) has comparable efficacy to conventional radiotherapy, with a lower incidence of adverse reactions. NRG-CC003 trial indicated that hippocampal avoidance prophylactic cranial irradiation (HA-PCI) reduced neurocognitive function (NCF) failure in comparison with PCI. This review provides references for clinical decision-making in lung cancer radiotherapy and future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.